In accordance with the disclosure in the Lucy Scientific Discovery Inc.s Form 10-K for the year ended June 30, 2023, the Company?s agreement with AJK Biopharmaceutical LLC ? Canadian Consulting Series, a limited liability company (the ?Agreement?), the principal for which is Assad J. Kazeminy, Ph.D., who, pursuant to the Agreement, had been serving as Chief Scientific Officer (a named executive officer) of the Company, has expired after a three-year term, effective February 22, 2024. No further action or arrangement has been made in relation to this expiration.